Leah Croll, MD, Assistant Professor of Clinical Neurology at the Lewis Katz School of Medicine at Temple University, offered perspective to ABC NewsOne about lecanemab, an experimental drug that in newly published data from a large, late-stage clinical trial has been shown to slow the rate of cognitive decline in early stage Alzheimer’s disease. The FDA still needs to approve the drug.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH